Strategic partnerships Burnet Institute actively collaborates with pharmaceutical and diagnostics partners, including Island Pharmaceuticals, Atomo Diagnostics, and Lumos Diagnostics, indicating a readiness to engage in co-development and testing initiatives that could be expanded to integrated research tools, analytics, or platform partnerships.

Global reach With offices in Australia, Myanmar, Papua New Guinea, and Vanuatu and ongoing infectious disease programs in the Indo-Pacific and Africa, Burnet presents opportunities for regional capacity building, field studies, and multi-country trials that could be served by scalable research services, training, and remote monitoring offerings.

Clinical research leadership The institute houses key leadership roles in infectious diseases and clinical research, including a joint appointment of a deputy director for disease elimination programs, signaling potential for consulting, protocol design, data analytics, and trial management services for global health projects.

Public health impact Active involvement in hepatitis and liver health initiatives and synergy with LiverWELL suggests potential for turnkey program support, including diagnostics, point-of-care solutions, and health systems integration to scale surveillance and elimination efforts.

Funding and grants Receives substantial funding and has government-backed support for diagnostics collaborations, presenting a pathway for co-funding, grant writing, and technology transfer opportunities in point-of-care testing, health metrics, and digital health platforms.